Related references
Note: Only part of the references are listed.A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: A meta-analytic/meta-regression study
Anand Kumar et al.
CRITICAL CARE MEDICINE (2010)
Initiation of Inappropriate Antimicrobial Therapy Results in a Fivefold Reduction of Survival in Human Septic Shock
Anand Kumar et al.
CHEST (2009)
Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy
Sean M. Bagshaw et al.
INTENSIVE CARE MEDICINE (2009)
Early intravenous unfractionated heparin and mortality in septic shock
Ryan Zarychanski et al.
CRITICAL CARE MEDICINE (2008)
Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008
R. Phillip Dellinger et al.
CRITICAL CARE MEDICINE (2008)
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii
Glenn A. Pankuch et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections
Michael D. Parkins et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Immortal time bias in observational studies of drug effects
Samy Suissa
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
Monotherapy versus combination therapy
Shilpa M. Patel et al.
MEDICAL CLINICS OF NORTH AMERICA (2006)
Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock
Arland Kumar et al.
CRITICAL CARE MEDICINE (2006)
Indications for propensity scores and review of their use in pharmacoepidemiology
RJ Glynn et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2006)
Revisiting combination antibiotic therapy for community-acquired invasive Streptococcus pneumoniae pneumonia
MA Mufson et al.
CLINICAL INFECTIOUS DISEASES (2006)
Propensity scores - An introduction and experimental test
JK Luellen et al.
EVALUATION REVIEW (2005)
The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia
K Weiss et al.
CHEST (2005)
Combination antibiotic therapy for Pseudomonas aeruginosa bacteraemia
M Paul et al.
LANCET INFECTIOUS DISEASES (2005)
Nonantimicrobial effects of antibacterial agents
TR Pasquale et al.
CLINICAL INFECTIOUS DISEASES (2005)
beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials
M Paul et al.
BMJ-BRITISH MEDICAL JOURNAL (2004)
Endotoxin neutralization and anti-inflammatory effects of tobramycin and ceftazidime in porcine endotoxin shock
G Goscinski et al.
CRITICAL CARE (2004)
Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis
N Safdar et al.
LANCET INFECTIOUS DISEASES (2004)
Cellular and molecular effects of macrolides on leukocyte function
MT Labro
CURRENT PHARMACEUTICAL DESIGN (2004)
Lack of synergy of erythromycin combined with penicillin or cefotaxime against Streptococcus pneumoniae in vitro
E Lin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Variation in the propensity to release endotoxin after cefuroxime exposure in different Gram-negative bacteria: Uniform and dose-dependent reduction by the addition of tobramycin
G Goscinski et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2003)
Pharmacokinetic-pharmacodynamic modeling of the inhibitory effect of erythromycin on tumour necrosis factor-α and interleukin-6 production
HJ Guchelaar et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2001)
Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents
E Gradelski et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2001)
Monotherapy versus combination therapy for bacterial infections
E Bouza et al.
MEDICAL CLINICS OF NORTH AMERICA (2000)
Interference of antibacterial agents with phagocyte functions: Immunomodulation or immuno-fairy tales?
MT Labro
CLINICAL MICROBIOLOGY REVIEWS (2000)
Share Paper
